Advancements in Cancer Drug Development: Sanofi’s Commitment to Impactful Therapies and Data Sharing at ASCO23

In the past two decades, we have witnessed remarkable advancements in cancer treatment, with groundbreaking approaches such as cellular therapy and immuno-oncology revolutionizing the field. The era of cancer drug development has shifted from molecule creation to identifying the most effective molecules to build, showcasing the ongoing scientific progress. Sanofi is dedicated to developing impactful therapeutic strategies that have the potential to significantly improve outcomes for cancer patients. At #ASCO23, we are excited to share data from our robust oncology portfolio and pipeline, including early results from our study on a natural killer (NK) cell engager targeting myeloid leukemia cells. For more insights on our research and collaborations, explore the latest findings and pursuits by our Head of Oncology Early Development, Giovanni Abbadessa.

Source:Peter Adamson/Linkedin